Context Therapeutics (CNTX) Income from Continuing Operations (2020 - 2026)
Context Therapeutics (CNTX) posted Income from Continuing Operations of 18292515.0 for Q1 2026, down 13.87% sequentially from 16063841.0 in Q4 2025, and down 300.22% YoY from 9136251.98 in Q1 2025.
Context Therapeutics (CNTX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Income from Continuing Operations for 7 years, with the latest figure at 18292515.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 300.22% year-over-year to 18292515.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 53701964.0 (up 3.96% YoY) and the FY2025 annual result came in at 72225986.0, down 40.29% from the prior year.
- Income from Continuing Operations slipped to 18292515.0 in Q1 2026 per CNTX's latest filing, from 16063841.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 3442962.0 in Q1 2022 and troughed at 28105778.0 in Q4 2024.
- A 5-year average of 10660301.18 and a median of 6790571.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations plunged 319.73% in 2022, then soared 45.29% in 2025.
- Over 5 years, Income from Continuing Operations stood at 13074083.0 in 2022, then tumbled by 80.04% to 23538508.0 in 2023, then retreated by 19.4% to 28105778.0 in 2024, then soared by 42.85% to 16063841.0 in 2025, then decreased by 13.87% to 18292515.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 18292515.0, 16063841.0, and 10488902.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | -14.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14.55 Mn |
| Mar 31, 2026 | -18.29 Mn |
| Dec 31, 2025 | -16.06 Mn |
| Sep 30, 2025 | -10.49 Mn |
| Jun 30, 2025 | -8.86 Mn |
| Mar 31, 2025 | -4.57 Mn |
| Dec 31, 2024 | -28.11 Mn |
| Sep 30, 2024 | -19.17 Mn |
| Jun 30, 2024 | -4.06 Mn |
| Mar 31, 2024 | -4.36 Mn |
| Dec 31, 2023 | -23.54 Mn |
| Sep 30, 2023 | -6.79 Mn |
| Jun 30, 2023 | -5.68 Mn |
| Mar 31, 2023 | -6.67 Mn |
| Dec 31, 2022 | -13.07 Mn |
| Sep 30, 2022 | -4.05 Mn |
| Jun 30, 2022 | -4.01 Mn |
| Mar 31, 2022 | -3.44 Mn |
| Dec 31, 2021 | -3.11 Mn |
| Sep 30, 2021 | -1.61 Mn |